Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap

Nov 28 2023

• By Joseph Haas

Dry eye disease — Aldeyra hopes it can quickly refile its NDA for dry eye disease • Source: Shutterstock

Related Content

Aldeyra Claims Success In Final Phase III For First-In-Class Dry Eye Drug

Jul 12 2022

Aldeyra All Set For Double Date With The FDA

Mar 10 2023

Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ

Nov 16 2023

Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss

Dec 22 2021

Aldeyra Allergic Conjunctivitis Drug Has Good Prospects With Phase III Results

Apr 27 2021

Related Companies

Aldeyra Therapeutics, Inc.

AbbVie Inc.

Additional Topics

Complete Response Letters Business Strategies Clinical Trials Drug Approval Standards Research & Development Ophthalmic BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window